Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ortiz, Tony
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia	Completed	2	359	US	LB-102	LB Pharmaceuticals Inc.	Schizophrenia	12/24	12/24
NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)	Recruiting	2	150	Canada, US, RoW	ML-004 (IR)/(ER) tablet, ML-004 Placebo	MapLight Therapeutics	Autism Spectrum Disorder	10/26	11/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ortiz, Tony
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia	Completed	2	359	US	LB-102	LB Pharmaceuticals Inc.	Schizophrenia	12/24	12/24
NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)	Recruiting	2	150	Canada, US, RoW	ML-004 (IR)/(ER) tablet, ML-004 Placebo	MapLight Therapeutics	Autism Spectrum Disorder	10/26	11/26